Profund Advisors
GLUE icon

Profund Advisors’s Monte Rosa Therapeutics GLUE Stock Holding History

Profund Advisors’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$387K Buy
32,406
+2,295
+8% +$39.3K 0.01% 647
2026
Q2 		$729K Sell
30,111
-16,573
-36% -$313K 0.02% 429
2026
Q1 		$768K Buy
46,684
+21,465
+85% +$410K 0.03% 420
2025
Q4 		$395K Buy
+25,219
New +$340K 0.01% 692

Other funds holding GLUE

Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $36.7B AUM 6.83% 1-Year Est. Return
ProShare Advisors
ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return
Virginia Retirement Systems
Virginia Retirement Systems Richmond, Virginia $16.3B AUM 35.33% 1-Year Est. Return
Wealth Effects
Wealth Effects Boston, Massachusetts $370M AUM 63.53% 1-Year Est. Return
Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $57B AUM 43.56% 1-Year Est. Return

Profund Advisors's GLUE Position: Q3 2026 in Review

Profund Advisors increased its Monte Rosa Therapeutics (GLUE) stake by 7.6% in Q3 2026, buying an estimated $39.3K and bringing the position to 32,406 shares worth $387K. The position accounts for 0.01% of the portfolio, ranked #647.

Profund Advisors first reported a position in GLUE in Q4 2025 and has held it in 4 quarters since. The position peaked at $768K in Q1 2026. 28 funds tracked by Wall St. Rank hold GLUE as of Q3 2026.

  • Profund Advisors held 32,406 shares of Monte Rosa Therapeutics worth $387K as of Q3 2026.
  • Profund Advisors bought 2,295 Monte Rosa Therapeutics shares in Q3 2026, an estimated $39.3K.
  • Monte Rosa Therapeutics made up 0.01% of Profund Advisors's portfolio in Q3 2026, its #647 holding.
  • Profund Advisors first reported a position in Monte Rosa Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • Profund Advisors's Monte Rosa Therapeutics position peaked at $768K in Q1 2026.
  • 28 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2026.

Based on Profund Advisors's 13F filing for Q3 2026, filed 29 Oct 2026.